Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Dermoklinika Centrum Medyczne s.c. M. Kierstan, J. Narbutt, A. Lesiak

Research site

Poland ul.Tadeusza Kościuszki 93, 90-436 Lodz, Poland

  • 1 trial recruiting
  • Dermatitis atopic · Epidermolysis bullosa
  • Adults and children

About Specializations

Dermoklinika Centrum Medyczne s.c. M. Kierstan, J. Narbutt, A. Lesiak in Lodz, Poland specialises in clinical trials of conditions such as Dermatitis atopic, Epidermolysis bullosa, and other specialisations. This site conducts important research.

Main research areas of the site

Skin and Connective Tissue Diseases

Clinical research at Dermoklinika Centrum Medyczne in Łódź is dedicated to advancing care for patients with skin and connective tissue disorders, seeking new therapies and better diagnostic tools.

  • Topical treatment evaluation for epidermolysis bullosa
  • Oral JAK inhibitor dosing studies for atopic dermatitis

Ongoing studies assess the efficacy and safety of innovative agents such as TCP-25 gel for wound healing in epidermolysis bullosa and soquelitinib for moderate to severe atopic dermatitis, aiming to expand therapeutic options for these conditions.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
ul.Tadeusza Kościuszki 9390-436 LodzPoland
Open in maps ↗
Recruiting now
1 trial
Conditions studied
2

More sites in LodzPoland

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

2 clinical trials

Epidermolysis bullosa

Recruiting

Study on the Effects of TCP-25 Gel for Wound Healing in Patients with Epidermolysis Bullosa

Investigational
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:H-GLY-LYS-TYR-GLY-PHE-TYR-THR-HIS-VAL-PHE-ARG-LEU-LYS-LYS-TRP-ILE-GLN-LYS-VAL-ILE-ASP-GLN-PHE-GLY-GLU-OH
  • Sponsor:Xinnate AB

Dermatitis atopic

Not yet recruiting

Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Adults with Moderate to Severe Atopic Dermatitis (Phase 2 Study)

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.